View ValuationNippon Shokubai 향후 성장Future 기준 점검 1/6Nippon Shokubai (는) 각각 연간 4.5% 및 4.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 5.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 5.2% 로 예상됩니다.핵심 정보4.5%이익 성장률5.58%EPS 성장률Chemicals 이익 성장17.2%매출 성장률4.2%향후 자기자본이익률5.24%애널리스트 커버리지Low마지막 업데이트13 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 14Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2026Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2026.공시 • Mar 27+ 1 more updateNippon Shokubai Co., Ltd. to Report Q1, 2027 Results on Aug 07, 2026Nippon Shokubai Co., Ltd. announced that they will report Q1, 2027 results at 1:00 PM, Tokyo Standard Time on Aug 07, 2026공시 • Feb 28Nippon Shokubai Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2026 results at 1:00 PM, Tokyo Standard Time on May 13, 2026공시 • Nov 18Nippon Shokubai Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Nippon Shokubai Co., Ltd. announced that they will report Q3, 2026 results at 1:00 PM, Tokyo Standard Time on Feb 05, 2026공시 • Aug 14Nippon Shokubai Co., Ltd. to Report Q2, 2026 Results on Nov 07, 2025Nippon Shokubai Co., Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025공시 • Jul 31Nippon Shokubai Co., Ltd. (TSE:4114) announces an Equity Buyback for 5,000,000 shares, representing 3.3% for ¥7,000 million.Nippon Shokubai Co., Ltd. (TSE:4114) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 shares, representing 3.3% of its issued share capital (excluding treasury stock), for a total purchase price of ¥7,000 million. The purpose of the program is to improve the shareholder return as well as capital efficiency and to implement flexible capital policy in response to change in the business environment. The program will be valid till February 27, 2026. As of June 30, 2025, the company has 151,691,868 issued shares (excluding treasury stock) and 4,308,132 treasury shares.공시 • Jun 26Nippon Shokubai's U.S. Group Company Acquires Iscc Plus Certification for Acrylic Acid and Superabsorbent PolymersNippon Shokubai Group companies in the United States have acquired ISCC PLUS certification for acrylic acid (hereinafter "AA") and superabsorbent polymers (hereinafter "SAP") produced locally. This enables Nippon Shokubai group to globally supply AA and SAP with a carbon footprint considered net zero. Through promoting the use of ISCC PLUS-certified AA and SAP, NipponShokubai Group aims to contribute to reducing environmental impact across the supply chain and to advancing a circular economy. Toward carbon neutrality by 2050, Nippon ShokubAI Group will continue to implement the "transformation" outlined in its long-term vision and mid-term management plan to enhance customer value. Nippon Shokubia Group commits and declares its compliance with the ISCC PLUS requirements in accordance with the latest ISCC regulations. ISCC (International Sustainability and Carbon Certification): It is a third-party certification program developed by International Sustainability and Carbon Certification (ISCC) system GmbH based in Germany to manage and guarantee sustainable raw materials and products such as biomass and recycled materials in the supply chain. Carbon footprint considered net zero: ISCC PLUS-certified products incorporate the biogenic CO2 removal associated with biomass growth into their carbon footprint calculations. The carbon footprints of these products are considered effectively net zero through the proportionally offset based on the share of biomass-derived feedstock allocated using the mass balance method. The mass balance method: When biomass-derived and petroleum-derived raw materials are used together in production, the proportion of biomass input can be allocated to specific end products. This method is officially recognized under the ISCC PLUS certification system.공시 • Jun 24Nippon Shokubai Plans to Expand Its Gmp-Compliant Nucleic Acid Drug API Manufacturing Capacity TenfoldNippon Shokubai CO., LTD. has announced a plan to expand its GMP (1)-compliant manufacturing capacity for nucleic acid drug "active pharmaceutical ingredients" (APIs) tenfold in response to rapidly growing global demand in the nucleic acid drug market. Nucleic acid drugs are generally defined as "chemically synthesized drugs with oligonucleotides as active ingredients that exert their effects without being translated into proteins." As a new modality following small molecule and antibody drugs, they are expected to be applied in areas such as rare diseases, neurological disorders, and cancers -- fields where conventional treatments have been limited. The capacity expansion will involve the installation of a large-scale production line with ten times the capacity (several kilograms per batch) of the company's existing line. The new facility is scheduled to begin operation in 2027, making it one of Japan's largest CDMOs, capable of manufacturing nucleic acid drug APIs for common diseases that require large-scale supply. The company will strengthen its manufacturing system to meet a wide range of needs, from non-clinical stages to large-scale commercial production. Leveraging Nippon Shokubai's long-standing expertise in organic synthesis and rigorous quality control systems, the company manufactures oligonucleotides and peptides, which are medium-sized molecule APIs. Its GMP-compliant facilities, among the most advanced in Japan, have been audited and visited by multiple pharmaceutical companies, all of which have given high evaluations, establishing Nippon ShokubAI's strong reputation in the industry. The company will continue to provide flexible contract manufacturing services that meet diverse needs and contribute to a sustainable society by ensuring a stable supply of medium-sized molecule APIs that support human health and life.공시 • May 31Nippon Shokubai Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Nippon Shokubai Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025공시 • May 13+ 3 more updatesNippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2025Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2025.공시 • Apr 02Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Emulsion Technology Co.,Ltd. from JSR Corporation.Nippon Shokubai Co., Ltd. (TSE:4114) agreed to acquire Emulsion Technology Co.,Ltd. from JSR Corporation for ¥7.2 billion on November 12, 2024. As part of consideration, ¥7.2 billion is paid towards common equity of Emulsion Technology Co.,Ltd. For the period ending March 31, 2024, Emulsion Technology Co.,Ltd. reported total revenue of ¥13.3 billion, EBIT of ¥918 million and net income of ¥647 million. The expected completion of the transaction is April 1, 2025. Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Emulsion Technology Co.,Ltd. from JSR Corporation on April 1, 2025.공시 • Feb 06Nippon Shokubai Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2025 results at 3:00 PM, Tokyo Standard Time on May 13, 2025공시 • Dec 12Nippon Shokubai Co., Ltd. (TSE:4114) acquired Lilac Pharma Co., Ltd.Nippon Shokubai Co., Ltd. (TSE:4114) acquired Lilac Pharma Co., Ltd. on December 9, 2024. Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Lilac Pharma Co., Ltd. on December 9, 2024.공시 • Nov 11Nippon Shokubai Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Nippon Shokubai Co., Ltd. announced that they will report Q3, 2025 results at 3:00 PM, Tokyo Standard Time on Feb 06, 2025공시 • Aug 15Nippon Shokubai Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024Nippon Shokubai Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024공시 • May 15Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 20, 2024Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 20, 2024.공시 • May 14Nippon Shokubai Co., Ltd. (TSE:4114) announces an Equity Buyback for 4,000,000 shares, representing 2.59% for ¥5,000 million.Nippon Shokubai Co., Ltd. (TSE:4114) announces a share repurchase program. Under the program, the company will repurchase up to 4,000,000 shares, representing 2.59% of its issued share capital (excluding treasury stock), for a total purchase price of ¥5,000 million. The purpose of the program is to improve the shareholder return as well as capital efficiency and to implement flexible capital policy in response to change in the business environment. The program will be valid till February 28, 2025. As of March 31, 2024, the company has 154,642,750 issued shares (excluding treasury stock) and 1,357,240 treasury shares.공시 • Mar 02Nippon Shokubai Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2024 results on May 13, 2024공시 • Feb 09+ 1 more updateNippon Shokubai Co., Ltd. Provides Dividend Forecast for the Fiscal Year Ending March 31, 2023Nippon Shokubai Co., Ltd. announced that For the fiscal year ending March 31, 2023, the company to forecasts to pay a dividend of JPY 90.00 per share as compared to JPY 90.00 per share paid a year ago.이익 및 매출 성장 예측OTCPK:NSHK.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/2029465,35019,70020,35056,60023/31/2028449,50018,65011,80053,20023/31/2027435,10017,4002,92049,43523/31/2026399,89816,7643,80953,544N/A12/31/2025400,05817,7407,02447,858N/A9/30/2025402,66716,0815,66849,535N/A6/30/2025405,49817,1973,06545,287N/A3/31/2025409,34617,39411,97046,974N/A12/31/2024408,26715,22819,28551,415N/A9/30/2024404,58413,07224,25447,508N/A6/30/2024399,74211,06439,47660,233N/A3/31/2024392,00911,00837,31357,880N/A12/31/2023386,3938,75933,85954,294N/A9/30/2023394,20112,18439,62060,584N/A6/30/2023405,42516,37620,07843,177N/A3/31/2023419,56819,39218,36241,447N/A12/31/2022425,01724,82316,62039,738N/A9/30/2022415,97325,43911,68733,270N/A6/30/2022394,74125,66816,66938,103N/A3/31/2022369,29323,72012,80235,058N/A12/31/2021347,5156,8977,46233,229N/A9/30/2021321,4832,63478928,640N/A6/30/2021296,284-6,8202,83232,011N/A3/31/2021273,163-10,8993,89135,277N/A12/31/2020270,5063,284-93234,167N/A9/30/2020273,5264,1804,14537,935N/A6/30/2020288,0969,393-1,49333,858N/A3/31/2020302,15011,0943,47037,499N/A12/31/2019298,16313,147N/A49,367N/A9/30/2019314,76616,652N/A48,327N/A6/30/2019326,68119,538N/A43,580N/A3/31/2019338,86923,849N/A35,918N/A12/31/2018347,43525,698N/A30,862N/A9/30/2018341,15925,195N/A29,595N/A6/30/2018331,68525,465N/A38,398N/A3/31/2018322,80124,280N/A38,823N/A12/31/2017327,82522,947N/A39,470N/A9/30/2017314,70622,870N/A38,590N/A6/30/2017302,27021,004N/A36,968N/A3/31/2017293,97019,361N/A37,474N/A12/31/2016284,71520,166N/A40,626N/A9/30/2016294,37320,028N/A44,579N/A6/30/2016310,20122,421N/A42,987N/A3/31/2016323,12426,003N/A53,264N/A12/31/2015347,36626,142N/A48,344N/A9/30/2015362,63526,089N/A45,438N/A6/30/2015368,54422,979N/A45,170N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: NSHK.F 의 연간 예상 수익 증가율(4.5%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: NSHK.F 의 연간 수익(4.5%)이 US 시장(16.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: NSHK.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: NSHK.F 의 수익(연간 4.2%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: NSHK.F 의 수익(연간 4.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: NSHK.F의 자본 수익률은 3년 후 5.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 21:32종가2026/03/02 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Nippon Shokubai Co., Ltd.는 12명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullAstris Advisory Japan, K.K.Mikiya YamadaBarclaysTakashi EnomotoBofA Global Research9명의 분석가 더 보기
공시 • May 14Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2026Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2026.
공시 • Mar 27+ 1 more updateNippon Shokubai Co., Ltd. to Report Q1, 2027 Results on Aug 07, 2026Nippon Shokubai Co., Ltd. announced that they will report Q1, 2027 results at 1:00 PM, Tokyo Standard Time on Aug 07, 2026
공시 • Feb 28Nippon Shokubai Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2026 results at 1:00 PM, Tokyo Standard Time on May 13, 2026
공시 • Nov 18Nippon Shokubai Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Nippon Shokubai Co., Ltd. announced that they will report Q3, 2026 results at 1:00 PM, Tokyo Standard Time on Feb 05, 2026
공시 • Aug 14Nippon Shokubai Co., Ltd. to Report Q2, 2026 Results on Nov 07, 2025Nippon Shokubai Co., Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025
공시 • Jul 31Nippon Shokubai Co., Ltd. (TSE:4114) announces an Equity Buyback for 5,000,000 shares, representing 3.3% for ¥7,000 million.Nippon Shokubai Co., Ltd. (TSE:4114) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 shares, representing 3.3% of its issued share capital (excluding treasury stock), for a total purchase price of ¥7,000 million. The purpose of the program is to improve the shareholder return as well as capital efficiency and to implement flexible capital policy in response to change in the business environment. The program will be valid till February 27, 2026. As of June 30, 2025, the company has 151,691,868 issued shares (excluding treasury stock) and 4,308,132 treasury shares.
공시 • Jun 26Nippon Shokubai's U.S. Group Company Acquires Iscc Plus Certification for Acrylic Acid and Superabsorbent PolymersNippon Shokubai Group companies in the United States have acquired ISCC PLUS certification for acrylic acid (hereinafter "AA") and superabsorbent polymers (hereinafter "SAP") produced locally. This enables Nippon Shokubai group to globally supply AA and SAP with a carbon footprint considered net zero. Through promoting the use of ISCC PLUS-certified AA and SAP, NipponShokubai Group aims to contribute to reducing environmental impact across the supply chain and to advancing a circular economy. Toward carbon neutrality by 2050, Nippon ShokubAI Group will continue to implement the "transformation" outlined in its long-term vision and mid-term management plan to enhance customer value. Nippon Shokubia Group commits and declares its compliance with the ISCC PLUS requirements in accordance with the latest ISCC regulations. ISCC (International Sustainability and Carbon Certification): It is a third-party certification program developed by International Sustainability and Carbon Certification (ISCC) system GmbH based in Germany to manage and guarantee sustainable raw materials and products such as biomass and recycled materials in the supply chain. Carbon footprint considered net zero: ISCC PLUS-certified products incorporate the biogenic CO2 removal associated with biomass growth into their carbon footprint calculations. The carbon footprints of these products are considered effectively net zero through the proportionally offset based on the share of biomass-derived feedstock allocated using the mass balance method. The mass balance method: When biomass-derived and petroleum-derived raw materials are used together in production, the proportion of biomass input can be allocated to specific end products. This method is officially recognized under the ISCC PLUS certification system.
공시 • Jun 24Nippon Shokubai Plans to Expand Its Gmp-Compliant Nucleic Acid Drug API Manufacturing Capacity TenfoldNippon Shokubai CO., LTD. has announced a plan to expand its GMP (1)-compliant manufacturing capacity for nucleic acid drug "active pharmaceutical ingredients" (APIs) tenfold in response to rapidly growing global demand in the nucleic acid drug market. Nucleic acid drugs are generally defined as "chemically synthesized drugs with oligonucleotides as active ingredients that exert their effects without being translated into proteins." As a new modality following small molecule and antibody drugs, they are expected to be applied in areas such as rare diseases, neurological disorders, and cancers -- fields where conventional treatments have been limited. The capacity expansion will involve the installation of a large-scale production line with ten times the capacity (several kilograms per batch) of the company's existing line. The new facility is scheduled to begin operation in 2027, making it one of Japan's largest CDMOs, capable of manufacturing nucleic acid drug APIs for common diseases that require large-scale supply. The company will strengthen its manufacturing system to meet a wide range of needs, from non-clinical stages to large-scale commercial production. Leveraging Nippon Shokubai's long-standing expertise in organic synthesis and rigorous quality control systems, the company manufactures oligonucleotides and peptides, which are medium-sized molecule APIs. Its GMP-compliant facilities, among the most advanced in Japan, have been audited and visited by multiple pharmaceutical companies, all of which have given high evaluations, establishing Nippon ShokubAI's strong reputation in the industry. The company will continue to provide flexible contract manufacturing services that meet diverse needs and contribute to a sustainable society by ensuring a stable supply of medium-sized molecule APIs that support human health and life.
공시 • May 31Nippon Shokubai Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Nippon Shokubai Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
공시 • May 13+ 3 more updatesNippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2025Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2025.
공시 • Apr 02Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Emulsion Technology Co.,Ltd. from JSR Corporation.Nippon Shokubai Co., Ltd. (TSE:4114) agreed to acquire Emulsion Technology Co.,Ltd. from JSR Corporation for ¥7.2 billion on November 12, 2024. As part of consideration, ¥7.2 billion is paid towards common equity of Emulsion Technology Co.,Ltd. For the period ending March 31, 2024, Emulsion Technology Co.,Ltd. reported total revenue of ¥13.3 billion, EBIT of ¥918 million and net income of ¥647 million. The expected completion of the transaction is April 1, 2025. Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Emulsion Technology Co.,Ltd. from JSR Corporation on April 1, 2025.
공시 • Feb 06Nippon Shokubai Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2025 results at 3:00 PM, Tokyo Standard Time on May 13, 2025
공시 • Dec 12Nippon Shokubai Co., Ltd. (TSE:4114) acquired Lilac Pharma Co., Ltd.Nippon Shokubai Co., Ltd. (TSE:4114) acquired Lilac Pharma Co., Ltd. on December 9, 2024. Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Lilac Pharma Co., Ltd. on December 9, 2024.
공시 • Nov 11Nippon Shokubai Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Nippon Shokubai Co., Ltd. announced that they will report Q3, 2025 results at 3:00 PM, Tokyo Standard Time on Feb 06, 2025
공시 • Aug 15Nippon Shokubai Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024Nippon Shokubai Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024
공시 • May 15Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 20, 2024Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 20, 2024.
공시 • May 14Nippon Shokubai Co., Ltd. (TSE:4114) announces an Equity Buyback for 4,000,000 shares, representing 2.59% for ¥5,000 million.Nippon Shokubai Co., Ltd. (TSE:4114) announces a share repurchase program. Under the program, the company will repurchase up to 4,000,000 shares, representing 2.59% of its issued share capital (excluding treasury stock), for a total purchase price of ¥5,000 million. The purpose of the program is to improve the shareholder return as well as capital efficiency and to implement flexible capital policy in response to change in the business environment. The program will be valid till February 28, 2025. As of March 31, 2024, the company has 154,642,750 issued shares (excluding treasury stock) and 1,357,240 treasury shares.
공시 • Mar 02Nippon Shokubai Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2024 results on May 13, 2024
공시 • Feb 09+ 1 more updateNippon Shokubai Co., Ltd. Provides Dividend Forecast for the Fiscal Year Ending March 31, 2023Nippon Shokubai Co., Ltd. announced that For the fiscal year ending March 31, 2023, the company to forecasts to pay a dividend of JPY 90.00 per share as compared to JPY 90.00 per share paid a year ago.